Teva Pharmaceuticals
TEVA
812 hedge funds and large institutions have $30B invested in Teva Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 304 increasing their positions, 299 reducing their positions, and 76 closing their positions.
32% more call options, than puts
Call options by funds: $945M | Put options by funds: $717M
2% more repeat investments, than reductions
Existing positions increased: 304 | Existing positions reduced: 299
0.28% less ownership
Funds ownership: 58.65% → 58.38% (-0.28%)
3% less funds holding
Funds holding: 836 → 812 (-24)
7% less capital invested
Capital invested by funds: $32.1B → $30B (-$2.11B)
23% less funds holding in top 10
Funds holding in top 10: 53 → 41 (-12)
25% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 76
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$713M |
| 2 |
PC
PointState Capital
New York
|
+$356M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$305M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$234M |
| 5 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$211M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$510M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$291M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$279M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$217M |
| 5 |
PC
Paulson & Co
New York
|
-$204M |
TEVA Hedge Fund Activity: Q2 2016 in Review
812 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2016, worth a combined $30B — down 6.6% from $32.1B a quarter earlier.
Sellers outnumbered buyers: 76 funds closed out of TEVA and 57 opened new positions — a net loss of 19 holders — while 299 trimmed existing stakes and 304 added.
The largest buyer was Barrow, Hanley, Mewhinney & Strauss, adding an estimated $713M. The largest seller was Fidelity Investments, cutting an estimated $510M.
- 812 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2016, down from 836 in Q1 2016.
- Funds reported $30B of Teva Pharmaceuticals stock for Q2 2016, down 6.6% quarter-over-quarter.
- 57 funds opened new Teva Pharmaceuticals positions in Q2 2016 and 76 closed out, a net change of -19 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2016 was Barrow, Hanley, Mewhinney & Strauss, an estimated $713M added.
- The largest Teva Pharmaceuticals seller in Q2 2016 was Fidelity Investments, an estimated $510M sold.
Based on aggregated 13F filings for Q2 2016.